TENZIN DECHEN: Open Payments
NPI 1043750318 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$619 in 5 payments from 5 companies in 2025. Trend: 2023 $18 · 2024 $604 · 2025 $619
Food & beverage: $619
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 1 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| ABBVIE INC. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $116 |
| Otsuka America Pharmaceutical, Inc. | 1 | $113 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, AUSTEDO XR, REXULTI.
Industry payments across PA — which companies pay providers there.
